Vera Therapeutics Stock Alpha and Beta Analysis
| VERA Stock | USD 27.99 0.33 1.19% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Vera Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Vera Therapeutics over a specified time horizon. Remember, high Vera Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Vera Therapeutics' market risk premium analysis include:
Beta 1.1 | Alpha (0.61) | Risk 3.99 | Sharpe Ratio (0.17) | Expected Return (0.69) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Vera |
Vera Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Vera Therapeutics market risk premium is the additional return an investor will receive from holding Vera Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Vera Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Vera Therapeutics' performance over market.| α | -0.61 | β | 1.10 |
Vera Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Vera Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Vera Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Vera Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Vera Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Vera Therapeutics shares will generate the highest return on investment. By understating and applying Vera Therapeutics stock market price indicators, traders can identify Vera Therapeutics position entry and exit signals to maximize returns.
Vera Therapeutics Return and Market Media
The median price of Vera Therapeutics for the period between Sat, Dec 14, 2024 and Fri, Mar 14, 2025 is 35.98 with a coefficient of variation of 17.42. The daily time series for the period is distributed with a sample standard deviation of 6.33, arithmetic mean of 36.33, and mean deviation of 5.4. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Disposition of 3772 shares by Fordyce Marshall of Vera Therapeutics at 41.3264 subject to Rule 16b-3 | 12/18/2024 |
2 | Acquisition by Fordyce Marshall of 57661 shares of Vera Therapeutics at 2.8968 subject to Rule 16b-3 | 12/19/2024 |
3 | Disposition of 1875 shares by Fordyce Marshall of Vera Therapeutics at 2.8968 subject to Rule 16b-3 | 12/24/2024 |
4 | Disposition of 15625 shares by Fordyce Marshall of Vera Therapeutics at 2.8968 subject to Rule 16b-3 | 12/27/2024 |
5 | Disposition of 9975 shares by Fordyce Marshall of Vera Therapeutics at 41.5335 subject to Rule 16b-3 | 01/08/2025 |
6 | Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFFAPRIL Inhibitor | 01/13/2025 |
7 | Vera Therapeutics Trading Up 4.9 percent - Still a Buy - MarketBeat | 01/30/2025 |
8 | Vera Therapeutics Raised to Strong-Buy at Wolfe Research | 02/05/2025 |
9 | Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 02/13/2025 |
10 | Vera Therapeutics stock drops amid rival drug update - Investing.com | 02/14/2025 |
11 | Acquisition by Johnson David Lee of 26900 shares of Vera Therapeutics subject to Rule 16b-3 | 02/18/2025 |
12 | Acquisition by Brenner Robert of 26900 shares of Vera Therapeutics subject to Rule 16b-3 | 02/20/2025 |
13 | Disposition of 10613 shares by Fordyce Marshall of Vera Therapeutics at 27.8933 subject to Rule 16b-3 | 02/21/2025 |
14 | Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results | 02/26/2025 |
15 | Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference | 02/27/2025 |
About Vera Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Vera or other stocks. Alpha measures the amount that position in Vera Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2024 | 2025 (projected) | Interest Debt Per Share | 0.85 | 0.49 | Revenue Per Share | 0.0392 | 0.0349 |
Vera Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Vera Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Vera Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Vera Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Vera Therapeutics. Please utilize our Beneish M Score to check the likelihood of Vera Therapeutics' management manipulating its earnings.
| 26th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Vera Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Vera Therapeutics Backtesting, Vera Therapeutics Valuation, Vera Therapeutics Correlation, Vera Therapeutics Hype Analysis, Vera Therapeutics Volatility, Vera Therapeutics History and analyze Vera Therapeutics Performance. For information on how to trade Vera Stock refer to our How to Trade Vera Stock guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Vera Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.